<?xml version='1.0' encoding='utf-8'?>
<document id="30578394"><sentence text="Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis." /><sentence text="PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis" /><sentence text=" We present results from our first clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF)" /><sentence text="This 12-week open-label study explored the safety, efficacy and pharmacokinetics of daily oral doses of 800 mg PBI-4050 alone and in combination with nintedanib or pirfenidone in patients with predominantly mild or moderate IPF"><entity charOffset="150-160" id="DDI-PubMed.30578394.s4.e0" text="nintedanib" /><entity charOffset="164-175" id="DDI-PubMed.30578394.s4.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30578394.s4.e0" e2="DDI-PubMed.30578394.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30578394.s4.e0" e2="DDI-PubMed.30578394.s4.e1" /></sentence><sentence text=" Nine patients received PBI-4050 alone, 16 patients received PBI-4050 with nintedanib and 16 patients received PBI-4050 with pirfenidone"><entity charOffset="75-85" id="DDI-PubMed.30578394.s5.e0" text="nintedanib" /><entity charOffset="125-136" id="DDI-PubMed.30578394.s5.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30578394.s5.e0" e2="DDI-PubMed.30578394.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30578394.s5.e0" e2="DDI-PubMed.30578394.s5.e1" /></sentence><sentence text="PBI-4050 alone or in combination with nintedanib or pirfenidone was well tolerated"><entity charOffset="38-48" id="DDI-PubMed.30578394.s6.e0" text="nintedanib" /><entity charOffset="52-63" id="DDI-PubMed.30578394.s6.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30578394.s6.e0" e2="DDI-PubMed.30578394.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30578394.s6.e0" e2="DDI-PubMed.30578394.s6.e1" /></sentence><sentence text=" Pharmacokinetic profiles for PBI-4050 were similar in the PBI-4050 alone and PBI-4050+nintedanib groups but reduced in the PBI-4050+pirfenidone group, suggesting a drug-drug interaction"><entity charOffset="78-97" id="DDI-PubMed.30578394.s7.e0" text="PBI-4050+nintedanib" /><entity charOffset="124-144" id="DDI-PubMed.30578394.s7.e1" text="PBI-4050+pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30578394.s7.e0" e2="DDI-PubMed.30578394.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30578394.s7.e0" e2="DDI-PubMed.30578394.s7.e1" /></sentence><sentence text=" There were no significant changes in forced vital capacity (FVC), either in % predicted or mL, from baseline to week 12 for PBI-4050 alone or PBI-4050+nintedanib"><entity charOffset="143-162" id="DDI-PubMed.30578394.s8.e0" text="PBI-4050+nintedanib" /></sentence><sentence text=" In contrast, a statistically significant reduction (p&lt;0" /><sentence text="024) in FVC % pred was seen for PBI-4050+pirfenidone after 12 weeks"><entity charOffset="32-52" id="DDI-PubMed.30578394.s10.e0" text="PBI-4050+pirfenidone" /></sentence><sentence text="There were no safety concerns with PBI-4050 alone or in combination with nintedanib or pirfenidone in IPF patients"><entity charOffset="73-83" id="DDI-PubMed.30578394.s11.e0" text="nintedanib" /><entity charOffset="87-98" id="DDI-PubMed.30578394.s11.e1" text="pirfenidone" /><pair ddi="false" e1="DDI-PubMed.30578394.s11.e0" e2="DDI-PubMed.30578394.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30578394.s11.e0" e2="DDI-PubMed.30578394.s11.e1" /></sentence><sentence text=" The stability of FVC between baseline and week 12 looked encouraging for PBI-4050 alone and in combination with nintedanib"><entity charOffset="113-123" id="DDI-PubMed.30578394.s12.e0" text="nintedanib" /></sentence><sentence text="" /></document>